Venetoclax Pharmacokinetics in Participants with End-stage Renal Disease Undergoing Hemodialysis.
Behnam NooraniRajeev M MenonXin ChenKennan C MarshWeize HuangShelly GuptaEdyta DobkowskaThomas C MarburyAhmed Hamed SalemPublished in: British journal of clinical pharmacology (2023)
ESRD and dialysis do not alter unbound venetoclax plasma concentrations. No dose adjustment is needed for patients with renal insufficiency based on pharmacokinetics.